These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35357885)

  • 1. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
    Hofste Op Bruinink D; Kuiper R; van Duin M; Cupedo T; van der Velden VHJ; Hoogenboezem R; van der Holt B; Beverloo HB; Valent ET; Vermeulen M; Gay F; Broijl A; Avet-Loiseau H; Munshi NC; Musto P; Moreau P; Zweegman S; van de Donk NWCJ; Sonneveld P
    J Clin Oncol; 2022 Sep; 40(27):3132-3150. PubMed ID: 35357885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
    van de Donk NWCJ
    J Clin Oncol; 2023 Mar; 41(7):1342-1349. PubMed ID: 36450104
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
    Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.
    Papadhimitriou SI; Terpos E; Liapis K; Pavlidis D; Marinakis T; Kastritis E; Dimopoulos MA; Tsitsilonis OE; Kostopoulos IV
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
    Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P
    Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
    Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
    Jelinek T; Bezdekova R; Zihala D; Sevcikova T; Anilkumar Sithara A; Pospisilova L; Sevcikova S; Polackova P; Stork M; Knechtova Z; Venglar O; Kapustova V; Popkova T; Muronova L; Chyra Z; Hrdinka M; Simicek M; Garcés JJ; Puig N; Cedena MT; Jurczyszyn A; Castillo JJ; Penka M; Radocha J; Mateos MV; San-Miguel JF; Paiva B; Pour L; Rihova L; Hajek R
    J Clin Oncol; 2023 Mar; 41(7):1383-1392. PubMed ID: 36315921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
    Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
    Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.
    Rojas EA; Corchete LA; Mateos MV; García-Sanz R; Misiewicz-Krzeminska I; Gutiérrez NC
    Blood Cancer J; 2019 Nov; 9(12):90. PubMed ID: 31748515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
    Tessier C; LeBlanc R; Roy J; Trudel S; Côté J; Lalancette M; Boudreault JS; Lemieux-Blanchard É; Kaedbey R; Pavic M
    Cancer Med; 2024 Sep; 13(17):e70192. PubMed ID: 39225552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
    Schinke C; Boyle EM; Ashby C; Wang Y; Lyzogubov V; Wardell C; Qu P; Hoering A; Deshpande S; Ryan K; Thanendrarajan S; Mohan M; Yarlagadda N; Khan M; Choudhury SR; Zangari M; van Rhee F; Davies F; Barlogie B; Morgan G; Walker BA
    Blood Cancer J; 2020 Jun; 10(6):70. PubMed ID: 32555163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma].
    Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of semi-quantitative parameters of
    Wan B; Zhang S; Wang P; Deng P; Dai W
    Ann Nucl Med; 2023 Mar; 37(3):155-165. PubMed ID: 36528697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
    Mai EK; Hielscher T; Bertsch U; Salwender HJ; Zweegman S; Raab MS; Munder M; Pantani L; Mancuso K; Brossart P; Beksac M; Blau IW; Dürig J; Besemer B; Fenk R; Reimer P; van der Holt B; Hänel M; von Metzler I; Graeven U; Müller-Tidow C; Boccadoro M; Scheid C; Dimopoulos MA; Hillengass J; Weisel KC; Cavo M; Sonneveld P; Goldschmidt H
    Leukemia; 2024 Mar; 38(3):640-647. PubMed ID: 38062124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.
    Usmani SZ; Nair B; Qu P; Hansen E; Zhang Q; Petty N; Waheed S; Shaughnessy JD; Alsayed Y; Heuck CJ; van Rhee F; Milner T; Hoering A; Szymonifka J; Sexton R; Sawyer J; Singh Z; Crowley J; Barlogie B
    Leukemia; 2012 Nov; 26(11):2398-405. PubMed ID: 22508408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
    Lionetti M; Musto P; Di Martino MT; Fabris S; Agnelli L; Todoerti K; Tuana G; Mosca L; Gallo Cantafio ME; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omede' P; Morabito F; Tassone P; Boccadoro M; Palumbo A; Neri A
    Clin Cancer Res; 2013 Jun; 19(12):3130-42. PubMed ID: 23613318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.